Floatz logo

Prochlorperazine

Headache Disorder

Wake Forest University Health SciencesSmall moleculePhase 4 / ApprovedDormant
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Headache Disorder cohort.

Asset / SponsorPhaseRating
Topiramate
University of Minnesota
Phase 4BBB
DFN-11 (SUMATRIPTAN INJECTION)
Danish Headache Center
Phase 4BBB
Lidocaine
Daniel A Tonetti, MD
Phase 4BBB
PROPOFOL
Medical College of Wisconsin
Phase 4BBB
Marcaine
HCA Florida North Florida Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

Prochlorperazine is also rated in:

migraine disorderActive
BBB
Indicative · Phase 4
74 / 100
View asset →
cancer of unknown primary siteDormant
B
Indicative · Phase 3
62 / 100
View asset →
autonomic facial cephalgiaDormant
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →